JP2016518379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518379A5 JP2016518379A5 JP2016509434A JP2016509434A JP2016518379A5 JP 2016518379 A5 JP2016518379 A5 JP 2016518379A5 JP 2016509434 A JP2016509434 A JP 2016509434A JP 2016509434 A JP2016509434 A JP 2016509434A JP 2016518379 A5 JP2016518379 A5 JP 2016518379A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- composition according
- sulfolobus
- variant
- fold protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000000499 gel Substances 0.000 claims 3
- 230000000699 topical effect Effects 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 241000205095 Sulfolobus shibatae Species 0.000 claims 2
- 241000205091 Sulfolobus solfataricus Species 0.000 claims 2
- 241000160715 Sulfolobus tokodaii Species 0.000 claims 2
- 229940047122 interleukins Drugs 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 229940123457 Free radical scavenger Drugs 0.000 claims 1
- 101100498534 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) dbp-7 gene Proteins 0.000 claims 1
- 102000043276 Oncogene Human genes 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 101000844743 Saccharolobus shibatae DNA-binding protein 7a Proteins 0.000 claims 1
- 101000844742 Saccharolobus shibatae DNA-binding protein 7b Proteins 0.000 claims 1
- 101000844745 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) DNA-binding protein 7a Proteins 0.000 claims 1
- 101000844752 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) DNA-binding protein 7d Proteins 0.000 claims 1
- 241000205098 Sulfolobus acidocaldarius Species 0.000 claims 1
- 101000844753 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) DNA-binding protein 7d Proteins 0.000 claims 1
- 101000844750 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) DNA-binding protein 7e Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000000058 anti acne agent Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124340 antiacne agent Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 229940125687 antiparasitic agent Drugs 0.000 claims 1
- 239000003908 antipruritic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 239000003410 keratolytic agent Substances 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000019612 pigmentation Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR13/53662 | 2013-04-22 | ||
| FR1353662A FR3004650B1 (fr) | 2013-04-22 | 2013-04-22 | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
| PCT/EP2014/058139 WO2014173899A1 (fr) | 2013-04-22 | 2014-04-22 | Compositions topiques comprenant des variantes de pli-ob |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019022358A Division JP2019112410A (ja) | 2013-04-22 | 2019-02-12 | Ｏｂフォールド変異体を含む局所用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016518379A JP2016518379A (ja) | 2016-06-23 |
| JP2016518379A5 true JP2016518379A5 (https=) | 2017-06-15 |
Family
ID=48795734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509434A Pending JP2016518379A (ja) | 2013-04-22 | 2014-04-22 | Ｏｂフォールド変異体を含む局所用組成物 |
| JP2019022358A Pending JP2019112410A (ja) | 2013-04-22 | 2019-02-12 | Ｏｂフォールド変異体を含む局所用組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019022358A Pending JP2019112410A (ja) | 2013-04-22 | 2019-02-12 | Ｏｂフォールド変異体を含む局所用組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10548945B2 (https=) |
| EP (1) | EP2988766B1 (https=) |
| JP (2) | JP2016518379A (https=) |
| CN (2) | CN105338995B (https=) |
| ES (1) | ES2637421T3 (https=) |
| FR (1) | FR3004650B1 (https=) |
| WO (1) | WO2014173899A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3004650B1 (fr) * | 2013-04-22 | 2015-05-29 | Affilogic | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
| FR3027521B1 (fr) * | 2014-10-24 | 2016-12-16 | Affilogic | Compositions pour administration par voie orale |
| EP3483180A1 (en) * | 2017-11-14 | 2019-05-15 | Affilogic | Multi specific molecules |
| EP3632924A1 (en) | 2018-10-07 | 2020-04-08 | Affilogic | Binders for inhibiting formation of multimeric proteins |
| WO2020231504A1 (en) | 2019-05-16 | 2020-11-19 | Massachusetts Institute Of Technology | Glycan-binding proteins and related compositions and methods |
| EP3878858A1 (en) | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
| EP4043481A1 (en) | 2021-02-15 | 2022-08-17 | Affilogic | Compounds and methods for extending half life of biomolecules |
| EP4059949A1 (en) | 2021-03-18 | 2022-09-21 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| EP4308590A1 (en) | 2021-03-18 | 2024-01-24 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| CN117106746B (zh) * | 2022-06-01 | 2024-11-22 | 北京擎科生物科技股份有限公司 | 逆转录突变体及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030228616A1 (en) * | 1999-10-29 | 2003-12-11 | Stratagene | DNA polymerase mutants with reverse transcriptase activity |
| NZ573407A (en) * | 2006-05-26 | 2012-09-28 | Obodies Ltd | Ob fold domains |
| ATE542830T1 (de) * | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
| EP3785735A1 (en) * | 2008-11-03 | 2021-03-03 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
| US20110098216A1 (en) * | 2009-10-22 | 2011-04-28 | Regen Therapeutics Plc | Therapeutic uses of colostrinin |
| EP2469278A1 (en) * | 2010-12-21 | 2012-06-27 | Institut Pasteur | Reagentless fluorescent biosensors from nanofitins, rational design methods to create reagentless fluorescent biosensors and methods of their use |
| FR2974816A1 (fr) * | 2011-05-04 | 2012-11-09 | Centre Nat Rech Scient | Methode de generation de proteines |
| FR3004650B1 (fr) * | 2013-04-22 | 2015-05-29 | Affilogic | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
| FR3027521B1 (fr) * | 2014-10-24 | 2016-12-16 | Affilogic | Compositions pour administration par voie orale |
| PL412787A1 (pl) * | 2015-06-22 | 2017-01-02 | Magdalena Król | Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną |
| WO2018048941A2 (en) * | 2016-09-08 | 2018-03-15 | The Board Of Trustees Of The Leland Stanford Junior University | Use of high affinity monoclonal antibody product binders to increase the duration of action of therapeutic monoclonal antibody products in a biologic tissue |
| EP3483180A1 (en) * | 2017-11-14 | 2019-05-15 | Affilogic | Multi specific molecules |
| EP3632924A1 (en) * | 2018-10-07 | 2020-04-08 | Affilogic | Binders for inhibiting formation of multimeric proteins |
| EP3878858A1 (en) * | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
| EP4059949A1 (en) * | 2021-03-18 | 2022-09-21 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
-
2013
- 2013-04-22 FR FR1353662A patent/FR3004650B1/fr not_active Expired - Fee Related
-
2014
- 2014-04-22 WO PCT/EP2014/058139 patent/WO2014173899A1/fr not_active Ceased
- 2014-04-22 US US14/786,287 patent/US10548945B2/en active Active
- 2014-04-22 CN CN201480030115.3A patent/CN105338995B/zh active Active
- 2014-04-22 CN CN202010402321.XA patent/CN111467477A/zh active Pending
- 2014-04-22 ES ES14718621.7T patent/ES2637421T3/es active Active
- 2014-04-22 JP JP2016509434A patent/JP2016518379A/ja active Pending
- 2014-04-22 EP EP14718621.7A patent/EP2988766B1/fr active Active
-
2019
- 2019-02-12 JP JP2019022358A patent/JP2019112410A/ja active Pending
- 2019-12-24 US US16/726,305 patent/US10898542B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518379A5 (https=) | ||
| Chaulagain et al. | Passive delivery of protein drugs through transdermal route | |
| EP4269560A3 (en) | Modified epidermal growth factor receptor peptides for use in genetically-modified cells | |
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| WO2018083087A3 (en) | Binding proteins | |
| JP2019507582A5 (https=) | ||
| CN115778904B (zh) | 一种用于体外转染和体内递送mRNA的制剂 | |
| EA202191027A2 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
| EA201992664A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака | |
| WO2007119011A3 (fr) | Proteines de fusion proteine n d'un virus de la famille des paramyxoviridae-proteine d'interet | |
| WO2019241893A3 (en) | Anti-her3 antibody and uses thereof | |
| WO2014160490A8 (en) | Antibody formulations | |
| MX2021001305A (es) | Anticuerpos anti-cxcr2 y usos de los mismos. | |
| WO2017066132A3 (en) | Synthetic antibody mimic peptides | |
| US20160143990A1 (en) | Topical Compositions Comprising OB-Fold Variants | |
| JP2014511682A5 (https=) | ||
| MX2019002664A (es) | Proteina de union a antigeno contra her3. | |
| WO2014144768A3 (en) | Bh4 stabilized peptides and uses thereof | |
| WO2023150724A3 (en) | Antigen binding proteins that bind b7-h3 | |
| JP2018500879A5 (https=) | ||
| Kang et al. | Control of spontaneous ovarian tumors by CD8+ T cells through NKG2D-targeted delivery of antigenic peptide | |
| Fernández et al. | Recent developments in engineering and delivery of protein and antibody therapeutics | |
| EA202190572A1 (ru) | Иммунотерапия раковых заболеваний рестриктированными по a*01 пептидами и комбинациями пептидов и относящиеся к ней способы | |
| WO2016081327A3 (en) | Recombinant expression of chlamydia momp antigen | |
| EA202190186A1 (ru) | Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака |